Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer

• Status: Terminated
• Trial end date: 2004-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

The epirubicin/docetaxel combination is one of the most active and best tolerated taxane/anthracycline combinations. In this phase II trial, we will further evaluate the feasibility, safety and effectiveness of the docetaxel/epirubicin combination, when administered as first-line treatment for metastatic breast cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: SCRI Development Innovations, LLC
• Collaborators: Aventis Pharmaceuticals; Pharmacia and Upjohn
• Treatments: Docetaxel; Epirubicin

Criteria

Inclusion Criteria:

To be included in this study, you must meet the following criteria:

• Metastatic breast cancer confirmed by biopsy.

• Received no previous chemotherapy for metastatic breast cancer.

• Prior hormonal therapy is acceptable.

• Measurable or evaluable disease.

• Able to perform activities of daily living without considerable assistance

• Adequate bone marrow, liver and kidney function

• Must be able to understand the nature of this study and give written informed consent.

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

• Age < 18 years.

• Cardiac ejection fraction < 45%.

• Women who are pregnant or lactating.

• Patients with meningeal metastases are ineligible.

• Moderate peripheral neuropathy

• History of hypersensitivity reaction to Taxotere

• Males with metastatic breast cancer

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.